The treatment of craniopharyngiomas is composed of an intricate balance of multiple modalities. Resection and radiotherapy have been combined to synergistically control tumor growth while preventing undue harm to crucial neurovascular structures. Although a craniopharyngioma is a benign lesion pathologically, it may induce severe neu rological injury due to its location and rate of growth. More recently, the advent of targeted, fractionated radiotherapy has allowed for more aggressive tumor control while reducing the necessity for large resections. Initial studies have demonstrated significant tumor control in patients who are treated with resection combined with radiation therapy, versus surgery alone, with a lower rate of treatment-associated neurological deficits. In this review, a detailed account of the current studies evaluating the role of stereotactic radiosurgery in the management of craniopharyngiomas is presented. The authors also provide a short account of their experience to aid in defining the role of CyberKnife ra diosurgery. (DOI: 10.3171/2010.2.FOCUS09311) 
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C raniopharyngiomas are benign extraaxial epithe lial tumors that arise from squamous epithelial remnants of the Rathke pouch, near the pituitary gland. 46 These cells may extend from the nasopharynx to the tuber cinereum and may arise within the sphenoid bone, the sella, or the suprasellar region. Although cra niopharyngiomas are rare, they are the most common su prasellar tumor in the pediatric age group, accounting for as many as 5% of all intracranial tumors or up to 10% of pediatric brain tumors. 72 The incidence of craniopharyn gioma has been estimated to be approximately 1.5 per million people per year, 7, 31 but may be considerably high er in specific ethnic groups, such as Japanese children (5.25 per million). 50 Craniopharyngiomas have a bimodal age distribution, generally appearing in young patients between the ages of 5 and 14 years and in adults between 50 and 74 years.
Although they are histologically benign, craniophar yngiomas can cause severe and often permanent damage to nearby hypothalamic, visual, and endocrine apparatus. The presentation of these tumors may include symptoms related to endocrine derangement of the hypothalamic pituitary axis, with severity dependent upon location, size, and rate of growth. Mass effect from hypothalam icpituitary axis dysfunction may result in increased in tracranial pressure presenting as headache, nausea, and vomiting. Cases with large mass lesions may also present with hydrocephalus (noted more commonly in children than in adults) as a result of the obstruction of the cere bral aqueduct or the interventricular foramina. 25, 39 Com pression of the nearby optic chiasm typically results in VFDs such as hemianopia and papilledema. Endocrine disruption often manifests as amenorrhea, hypothyroid ism, and diabetes insipidus. 24, 28 The structural composition of these tumors may in clude solid, cystic, mixed solid and cystic, or calcified components. Traditionally, craniopharyngiomas have been separated into either the adamantinomatous or pap illary variety. More commonly observed in the pediatric population, the adamantinomatous type is characterized as calcified with mixed composition. Papillary cranio pharyngiomas observed in adults are often more solid.
Current treatment strategies for craniopharyngiomas include cystic drainage, intracavity chemotherapy, limited resection or GTR, and radiation therapy. These strategies are often combined into a patient-specific treatment plan based on age at presentation, tumor size, relation to op tic chiasm and third ventricle, presence of hydrocepha The role of radiosurgery in the treatment of craniopharyngiomas lus, and degree of pituitary endocrinopathy. If total exci sion can be safely performed with minimal risk to these structures, then surgery remains the treatment of choice because it allows rapid decompression, minimizes recur rence, and provides a histological diagnosis. However, judgment of minimal risk is often unclear as some favor STR coupled with adjunctive therapy to achieve similar outcomes. 9, 18, 34, 35, 38, 43, 80, 82, 92 Although surgical approaches are often curative, they can produce high treatmentrelated morbidity and even death due to the close proximity of crucial neurovascular structures. Recurrent craniopharyn giomas must be considered separately, because secondary surgery is associated with a higher risk of complications and a lower cure rate. 8, 18, 21, 29, 57, 87 More recently, SRS tech niques have become increasingly used as either a primary or secondary treatment for patients with craniopharyn gioma.
Surgical Outcomes
Complete resection of craniopharyngiomas is a pri mary objective and has curative potential. In a recent patient series studied by Shi et al., 77 284 patients (58 children) were treated surgically with no adjunctive ther apy between 1996 and 2006. Gross-total resection, STR, and partial removal of the tumors was achieved in 237 (83.5%), 34 (12.0%), and 13 patients (4.5%), respectively. Upon followup, 23 patients (14.1%) experienced recur rence 1.0 to 3.5 years after GTR, and 24 (64.9%) tumors recurred 0.25-1.5 years after STR or partial resection. In this series, the early mortality rate was 4.2%. In another 25year retrospective study by Van Effenterre and Boch, 85 122 patients underwent either GTR (59%), STR (29%), or partial resection (12%). During the followup period, 29 patients (24%) experienced 1 or more recurrences. The delay to recurrence ranged from 1 to 180 months (mean 42 months, median 12 months). In this study, 13% of pa tients in whom a GTR was achieved experienced tumor recurrence; 33% with STR experienced recurrence; and 69% with partial removal suffered a recurrence of tumor. Radiotherapy was not systematically administered and was only reserved for cases of recurrence. The surgical mortality rate was 2.5%, and overall patient survival was 95% at 2 years, 91% at 5 years, and 83% at 10 years.
The comparison of surgical complications for cra niopharyngiomas across various patient series produces a variable picture. Most of the recent large patient series report a GTR rate of 59 to 90%. 18, 33, 85, 89 The 10year recur rencefree survival rates have been reported as 74 to 81% for GTR, 1, 19, 87 41 to 42% after partial removal, 32,69 and 83 to 90% after a combination of surgery and radiotherapy. 32, 69 Surgical mortality rates in these series vary between 1.1 and 4.2%. 18, 76, 85, 89 It is well documented that recurrent tumors are associated with significantly higher risk and poorer outcome, with overall mortality rates reported to be between 10.5 and 40.6%. 18, 89 Pituitary dysfunction may occur in 50 to 100% of patients, with diabetes insipidus as the most common dysfunction. Visual deterioration may occur in up to 50% of patients undergoing GTR for cra niopharyngiomas. 45 
Radiation Therapy
Although surgical drainage or resection of cranio pharyngiomas may be the initial step in management, the rate of complete obliteration is low using only 1 modality. The fine balance between further neurological deficit and complete tumor resection has led to the use of various noninvasive forms of therapy. Radiation therapy is often applied during the postoperative course in the event of STR or tumor recurrence. Frequently, external radiation therapy is the preferred strategy, but in recent years endo cavitary/intracavitary radiation and SRS have also dem onstrated efficacy in tumor control.
Proton Beam Radiotherapy
Proton beam radiotherapy, a specific form of confor mal external beam therapy, is used as an adjuvant and/or salvage treatment modality for craniopharyngiomas, par ticularly those in the pediatric population. In a retrospec tive study by Luu and colleagues, 53 16 patients (ages 7-34 years) were treated with proton beam radiation. A daily dose of 1.8 CGE was used for a total CGE of 50.4 to 59.4. Local tumor control was achieved in 14 patients with few acute side effects. The authors reasoned that if the dose to the optic pathway was kept below 55 CGE, the rate of complication would be < 10% with minimal damage to the optic apparatus. In a similar study by Fitzek et al., 22 15 patients with craniopharyngioma were treated with com bined protonphoton irradiation at a median dose of 56.9 CGE. The actuarial 10year survival rate was 72% and the 10year local control rate was 85%. Two patients suf fered visual defects (hemianopia and total loss of vision) after receiving doses of 64 and 55.3 CGE, respectively, to their optic chiasm. 67, 88 However, because in tracavitary irradiation is limited to cystic tumors, recur rence and survival rates using only this type of therapy are considered inferior to those of surgery or external ra diotherapy. 36, 88 Additionally, the risk of visual deteriora tion is considerable, possibly due to unpredictable radia tion dose to the optic pathway and radiation damage from leakage. In a review by Cáceres, 7 the numbers of patients experiencing no change or improvement in visual acuity after intracavitary irradiation ranged from 42 to 99% of the different series, whereas 31 to 58% experienced dete rioration in visual function.
Endocavitary Radiation Therapy

External Radiation Therapy
Fractionated radiation therapy improves craniophar yngioma control and survival 23, 49, 56, 65, 69, 74 and is the stan dard treatment for residual or recurrent tumor. Most pa tient series demonstrate that when combined with STR, adjuvant radiotherapy allows for greater tumor control and survival than surgery alone. 30, 32, 70, 71, 79, 86 In a study by Varlotto et al., 86 an 89% tumor control rate was noted in patients who received both STR and external beam ir radiation. Stripp and colleagues 79 compared 57 patients treated only with surgery to 18 patients treated with STR combined with radiation therapy, and demonstrated a 10year tumor control rate of 42 and 84%, respectively. The case for using primary radiation therapy for recur rent craniopharyngioma is even stronger, showing a lower risk of recurrence (30%) and better outcome (90%, 10 year PFS). 41, 43, 44, 62 Finally, Karavitaki and colleagues 45 examined the records of 121 patients and subdivided the patients into 4 treatment categories: GTR, GTR with ra diotherapy, partial removal, and partial removal with ra diotherapy. The recurrencefree survival rate was 100% at 10 years in the GTR only and GTR with radiotherapy groups, 38% in the partial removal group, and 77% in the partial removal with radiotherapy group. When using radiotherapy, the risk of neurotoxic ity from radiation injury should be considered alongside gains in potential tumor control. Doses of 50-60 Gy are most commonly used. 86 Conventionally fractionated focal radiation therapy around the sellarsuprasellar region is also associated with risks similar to surgery. Disruption of the hypothalamicpituitary axis may result in diabetes insipidus, panhypopituitarism, hypogonadism, hypotha lamic obesity, or sleep disturbance. 2, 14, 54 The normal optic apparatus is particularly sensitive to radiation; optimized dose and fractionation regimes carry a 3% risk of optic neuropathy. 20, 55, 63 There is also considerable discussion about the effect of radiation on cognitive function, an issue particularly pertinent in the pediatric population. Addi tionally, radiation itself carries the risk of secondary ma lignancies, 5, 73, 83 radiation necrosis, 37, 83 and vasculopathy, which also have secondary neurodegenerative effects.
Typically, craniopharyngiomas are treated with radi ation doses between 45 and 55 Gy in 1.8 to 2 Gy fractions to prevent growth of tumor and minimize injury to the visual pathways. Longterm (10year) local control ranges from 31 to 42% with surgery alone compared with 57 to 89% with surgery and radiotherapy. 30, 32, 69, 71, 79, 86 However, there are limitations, as the wide treatment field includes irradiating many structures, such as the optic apparatus, pituitary gland, hypothalamus, and medial temporal lobe. The risk may only manifest itself after a long delay, but this issue is particularly important because benign condi tions such as craniopharyngiomas confer favorable long term survival and have a predilection for the pediatric population. Another limitation of radiation therapy is that when conventional radiotherapy fails, it almost inevitably precludes further radiotherapy treatment to the recurrent tumor. Finally, although of minor importance, conven tional fractionated radiotherapy usually takes place over a 6week course, which is less attractive to patients when compared with other shorter treatment courses. For these reasons, radiosurgery (particularly multisession radiosur gery) may present a more practical option, especially for treating those tumors surrounding the optic apparatus.
Stereotactic Radiosurgery
Stereotactic radiosurgery is a relatively recent thera peutic option for craniopharyngioma that has significantly improved the effectiveness of, and morbidity associated with, radiation therapy. With SRS, 1 to 5 radiation treat ments are used to treat residual or recurrent lesions. The application of stereotaxis for target localization, treatment planning, and daily treatment immobilization allows for a more precise delivery of radiation dose, with a steeper dose gradient between tumor and parenchymal tissue to prevent further neurological deficit. The radiation dose can be delivered using either a multiple cobalt60 gamma radiation-emitting source such as the GK or a modified linear accelerator (CyberKnife). Most stereotactic sys tems can deliver a radiation beam to within approximate ly 1 mm of the lesion. Historically, SRS for craniophar yngiomas was limited to tumors 3 cm or less in size that were 3 to 5 mm away from the optic chiasm and nerves. In the case of single-session SRS, the optic chiasm be comes a limiting anatomical structure capable of only receiving 8 to 10 Gy per session before the incidence of optic neuropathy increases. 27, 51 More recent multisession SRS using image-guided radiosurgical techniques has al lowed for treatment of craniopharyngiomas immediately adjacent to the anterior visual pathways. 1 In the current literature, several studies have reported safe and effective longterm results with the application of SRS using the GK for the treatment of craniopharyn giomas. 10, 48, 75, 84 Kobayashi et al. 47 published the largest treatment and outcomes series, involving 98 cases. At a mean marginal dose of 11.5 Gy and a mean tumor size of 3.5 cm 3 , these authors observed a tumor control rate of 79.6%, with a complete response in 19.4% and partial re sponse in 67.4% of the cases. The actuarial 5 and 10year survival rates were 94.1 and 91%, respectively, with re spective PFS rates of 60.8 and 53.8%. Also within the last year, Yomo and colleagues 90 demonstrated the outcomes in 18 patients with residual or recurrent craniopharyngio ma who were treated using the Leksell GK Model C. Tu mor growth was controlled in 17 cases (94%), and volume reduction was attained in 13 cases (72%). Mean tumor volume was 1.8 cm 3 and the mean marginal radiation dose was 11.6 Gy. No new endocrinopathy was observed and 3 patients experienced substantial improvement of visual functions following shrinkage of the neoplasm. In anoth er study by Chung et al., 11 tumor control was achieved in 87% of the 31 patients in the study, and 84% demon strated fair to excellent clinical outcomes. Minniti et al. 58 completed a large metaanalysis of 8 published studies that included 252 patients who underwent either unfrac tionated radiosurgery or GK therapy, demonstrating a tumor control rate of 69%. Taken together (Table 1) , the published studies on GK therapy for craniopharyngiomas demonstrate an average control rate of 90% for solid tu mors, 88% for cystic tumors, and 60% for mixed tumors. Tumor control was achieved with a mean marginal dose of 12 Gy and recurrence of tumor was observed in 85% of cases that received a marginal dose < 6 Gy.
Given the current advances in imageguided radio surgical technology, the principle of multisession delivery of SRS can be incorporated with the anatomical precision and conformality of radiosurgery. This incorporation al lows for the precise delivery of potentially safer radiation doses than encountered in single session radiosurgery, while exploiting the volume effect by applying higher and more effective doses than was possible using convention al radiation therapy. The multisession delivery approach is particularly pertinent in treating craniopharyngiomas, which are often located near delicate neurovascular struc tures. The tolerance of these critical structures to radia tion depends on the amount of radiation received, volume of tissue irradiated, previous insult, and prior radiother apy. Due to the proximity of the tumors to the optic ap paratus, only a single dose of 8 to 10 Gy is tolerable to avoid damage to the nearby structures. 36 Higher doses to optic nerves are associated with increasing rates of defi cit. Leber et al. 51 reported that optic neuropathy occurred in 22 patients (26.7%) who received 10 to 15 Gy and 13 patients (78%) who received > 15 Gy, whereas 31 patients who received < 10 Gy were without optic insult. Like wise, Stafford and colleagues 78 observed radiation optic neuropathy in 1.7% of patients who received < 8 Gy, in 1.8% of patients who received 8-10 Gy, and in 6.9% of patients who received > 12 Gy after treatment with the GK for benign tumors of the sellar or parasellar region.
Cyberknife SRS: Our Experience
The CyberKnife (Accuray, Inc.) consists of a minia ture lightweight linear accelerator mounted on a robotic arm with 6° of freedom of movement. This configura tion allows unobstructed access to the entire body and a photon beam can be targeted with submillimeter accu racy 64 ( Fig. 1) . The CyberKnife employs an image-guided control loop with target tracking capabilities, thus it can adjust for patient movement and obviates the use of in vasive frames to stabilize the patient. Patients do wear a thermoplastic mask that can be used for multisession SRS (hypofractionation) in patients with tumors near eloquent structures, allowing higher doses of radiation to be deliv ered over a longer period of time.
In a study by Lee et al., 52 11 patients with residual craniopharyngiomas within 2 mm of the optic appara tus or pituitary gland were treated using the CyberKnife SRS system. The clinical presentation, surgical history, radiation received, and outcome of these 5 male and 6 female patients with an average age of 34.5 years are documented in Table 2 . A mean marginal dose of 21.6 Gy prescribed to a mean isodose line of 75% was applied over multiple sessions. The mean maximum dose was 29.9 Gy and the mean target volume was 6 cm 3 (Table 3) . Patient outcomes were quantified using MR imaging and formal Goldman visual field assessments at 6-month in tervals for 2 years, then once every year (Table 4 ). Prior to CyberKnife therapy, 10 patients suffered from a degree of visual loss, while 5 had endocrine abnormalities requiring hormonal replacement. Ten patients had operative reports documenting an STR with radiological confirmation, and 1 underwent a complete resection with followup MR imaging demonstrating recurrence 1 year after surgery. Residual tumor was most often located in the suprasellar region, and in 10 cases was found to be against or displac ing the optic nerve or chiasm. The pituitary stalk only was compressed in 1 patient.
The mean followup time was 15.4 months (range 4-64 months). All 10 patients with visual field or acu ity problems either improved or remained stable after CyberKnife radiosurgery. In this series, treatment plans were designed to keep the dose experienced by the op tic apparatus to < 5 Gy during any single session. The volume of the optic apparatus that received 80% of the prescribed dose was < 0.05 cm 3 , whereas the volume that received 50% of the dose was < 0.5 cm 3 . Therefore, the actual volume of the optic segment that received 5 Gy would be small relative to the total volume of the optic apparatus. Preservation of baseline visual function is sup ported by our previous work, which showed that the risk of visual loss with multisession radiosurgery appears to be low for perioptic tumors. 1, 66 Radiationinduced optic neuropathy is a known entity that tends to present over the course of several years, but the short followup dura tion of our study prevents making definitive conclusions regarding the effect of multisession therapy.
There were no new neuroendocrine problems and the 5 patients with endocrine derangement remained stable, with no new deterioration after CyberKnife treatment. Tu mor shrinkage was observed in 7 patients, with 3 of these tumors remaining the same at 2 years after treatment, resulting in a 91% tumor control rate. One patient devel oped a cystic enlargement of the residual tumor without any worsening symptoms or signs. Irradiation of cystic craniopharyngiomas may result in cystic enlargement, which does not represent tumor recurrence and may later regress. 13 In our series, the patient's symptoms remained stable, but rigorous clinical and radiological assessment is critical, including visual and neuroendocrine assessment. We believe that multisession treatment regimens mini mize the risk to the optic apparatus and pituitary gland while delivering an appropriate amount of radiation for disease control.
There are several assumptions that contributed to do simetry calculations for stereotactic radiation delivery. In a review by Timmerman et al., 81 the authors outlined 3 requirements necessary for a successful treatment: 1) the ability to describe the location of the target; 2) the ability to shape the prescription isodose surface to the surface of the target volume; and 3) the ability to construct radiation dose distributions with very rapid falloff dose to spare surrounding healthy tissue. In calculating dosimetry, the best approach is to have multiple beam directions, which allows for attenuation of the primary beam outside of the targeted areas using multileaf collimators.
Radiosurgical Dosing
Several factors influence the choice of radiosurgical dose, including the pathology of the lesion, the nature of the adjacent tissues, and the volume of both of these structures. Much of what we know about the tolerance of normal brain structures came from studies using con ventional radiation therapy and single fraction radiosur gery. As discussed, the CyberKnife, with its frameless platform, allows for multisession schedules. Multisession radiation allows sublethal injury to normal tissue, which can repopulate between fractions; other advantages in clude achieving higher tumor cell death by reoxygenation of hypoxic cells, and reassortment of cells into sensitive phases of the cell cycle.
To estimate the BED of different fractionation schemes, the linear quadratic model of cell survival from radiation is used. 40 Multifraction treatments were con verted to a singlefraction BED using the linear quadratic model:
where n represents the number of fractions, d represents dose per fraction, and α/β represents the alpha/beta ratio. 16 The ratio of α/β reflects the radiosensitivity of the cell * FSRT = fractionated stereotactic radiotherapy; GKS = Gamma Knife surgery; NA = not available; SCRT = stereotactically guided conformational radiotherapy being exposed; the higher the α/β ratio, the more radio sensitive the cell. Various studies have shown that cranial nerve neuropathies occurred in 1 to 3% of cases when the brainstem was irradiated to 12 to 13 Gy. We have cho sen to use a fractionation scheme when the single fraction dose exceeds 13 Gy to more than 20% of the brainstem, as is often encountered in craniopharyngiomas. In addi tion, we limit the single fraction dose to the optic appara tus to < 10 Gy by utilizing a fractionation scheme of 2 to 5 fractions and limiting the exposure to the optic apparatus to < 5 Gy per fraction. Using these parameters, we have been able to preserve preradiation visual function in 94% of cases involving perioptic lesions. 1 The exact α/β ratio of craniopharyngiomas is un known, but others have used a ratio of 2. 86 By assuming an α/β ratio of 2, we can calculate that a radiation schedule of 25 Gy in 5 sessions estimates a singledose equivalent of 12.3 Gy, a dose that approaches our intended target.
Conclusions
Optimal management of craniopharyngiomas re mains controversial. The often peculiar location of a craniopharyngioma implicates vital structures that may be subjected to undue harm after radiotherapy. Thus, a custom multimodality treatment strategy is employed to optimize outcome. Radiotherapy has a definitive role in the treatment of craniopharyngiomas, both as an adjuvant therapy following primary STR and also as a primary treatment for recurrent disease. Our experience demon strates that multisession therapy may prevent unintended consequences to surrounding optic structures and provide significant disease control. Although further long-term studies are required to fully evaluate clinical outcome, current evidence suggests beneficial results of radiothera py for craniopharyngiomas.
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